Stock 0LER TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Teva Pharmaceutical Industries Limited London S.E.

Equities

0LER

US8816242098

Market Closed - London S.E.
Other stock markets
 11:30:00 2024-05-31 am EDT 		5-day change 1st Jan Change
16.9 USD +3.21% Intraday chart for Teva Pharmaceutical Industries Limited +1.19% +61.95%
May. 30 Teva Pharmaceutical Gains FDA Approval for Daily Huntington's Disease Pill MT
May. 30 Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24?48 mg/day) CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24?48 mg/day)
CI
Teva Pharmaceutical Industries Limited and Alvotech Announce SIMLANDI® Injection Now Available in the U.S
CI
Sector Update: Health Care Stocks Slipping Wednesday Afternoon
MT
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed
MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday
MT
Sector Update: Health Care
MT
Teva Pharmaceutical Industries Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed
MT
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 Revenue $3.82B
MT
Earnings Flash (TEVA) TEVA PHARMACEUTICAL INDUSTRIES LIMITED Posts Q1 EPS $0.48
MT
Teva Pharm Q1 profit falls short of estimates, revenue gains
RE
Teva Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024
CI
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent
MT
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. 0LER Stock
  5. News Teva Pharmaceutical Industries Limited
  6. Highlights